Becton Dickinson with cautious analyst tone, shares tick higher in S&P 500 trade

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 14:37.

Becton Dickinson (US0718131099) remains on the radar of NYSE investors after a recent recovery in the shares within the S&P 500 healthcare cohort. Market commentary highlights both valuation concerns and operational resilience in the medtech group.

What recent commentary shows

On 27 June, market portal finanzen100 pointed to a roughly 3 percent advance in Becton Dickinson shares in the latest session, noting ongoing debate about whether the stock still trades below fair value based on fundamental metrics. The finanzen100 overview on Becton Dickinson cites a recent GuruFocus take that assigns the company a GF Score of 76 out of 100, which reflects solid but not outstanding growth, profitability and financial strength.

The same news flow highlights an insider transaction from 25 June, when Michael Garrison, a senior Becton Dickinson executive, sold 1,100 shares according to filings referenced by GuruFocus. GuruFocus insider data on BDX frames the sale as relatively small compared with Garrison’s remaining holding, but investors often treat such moves as a signal to scrutinize valuation and growth prospects more closely.

Analyst views and consensus backdrop

Beyond individual insider moves, analysts remain split on the medtech name. GuruFocus recently summarized that Bank of America had trimmed its price target for Becton Dickinson to reflect persisting headwinds in parts of the medical technology space, while retaining a generally constructive long-term view on the business model. A GuruFocus note on BofA’s stance toward BDX points to slower demand in some capital equipment categories and pricing pressure in selected consumables as reasons behind the cautious adjustment.

At the same time, consensus data compiled by MarketBeat indicate that a majority of covering analysts still rate Becton Dickinson stock at Hold or Buy, with the shares recently closing at around 156 dollars on the NYSE on 26 June. MarketBeat’s analyst ratings overview for BDX shows a blended picture: growth and margin improvement in diagnostics and interventional segments are offset by concerns about capital spending cycles and currency effects.

The products behind the medtech group

Becton Dickinson generates its revenue mainly from medical devices, consumables and diagnostic systems used in hospitals, laboratories and outpatient settings worldwide. A flagship product line is its BD Vacutainer blood collection systems, which are widely deployed in clinical laboratories for routine testing and play a central role in recurring consumables revenue.

Where the shares trade now

The Becton Dickinson shares (US0718131099) last closed on the NYSE at 156.06 US dollars on 2026-06-26, 15:59 Eastern Time, according to MarketBeat and exchange data.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All data are based on sources considered reliable but without any guarantee. Investors should conduct their own research and, where appropriate, consult a qualified financial advisor before making investment decisions.